Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$12.83
-1.2%
$12.97
$10.95
$13.42
N/AN/A101,797 shs96,528 shs
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
C$0.11
C$0.11
C$0.02
C$0.16
C$952KN/A3.16 million shs1.31 million shs
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$19.10
+0.1%
$19.10
$18.63
$27.54
$1.91MN/A1,912 shs19,400 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
+0.08%+2.20%+1.41%+6.13%+14.96%
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
0.00%0.00%0.00%0.00%0.00%
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00
N/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$39.39MN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AC$0.01 per share8.75C$0.00 per shareN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/A0.00N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A-C$0.01N/AN/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
$1.3910.83%+12.82%N/A2 Years
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$0.080.42%N/AN/AN/A

Latest ICO, BGT, and QPT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1210.98%4/12/20244/15/20244/30/2024
3/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1211.07%3/14/20243/15/20243/28/2024
2/1/2024
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
Monthly$0.1211.65%2/14/20242/15/20242/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A
1.14
1.12
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BlackRock Floating Rate Income Trust stock logo
BGT
BlackRock Floating Rate Income Trust
N/AN/AN/ANot Optionable
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A9.07 millionN/ANot Optionable
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/A100,000N/ANot Optionable

ICO, BGT, and QPT Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BlackRock Floating Rate Income Trust logo

BlackRock Floating Rate Income Trust

NYSE:BGT
BlackRock Floating Rate Income Trust is a close ended fixed income mutual fund launched by BlackRoack Inc. The fund is co-managed by BlackRock Advisors, LLC and BlackRock Financial Management, Inc. It invests in the fixed income markets across the globe while focusing on the United States. The fund invests in bonds of companies operating across diversified sectors. It invests in corporate bonds with average effective duration of its portfolio will be no more than 1.5 years. The fund was formerly known as BlackRock Global Floating Rate Income Trust. BlackRock Floating Rate Income Trust was formed on August 30, 2004 and is domiciled in the United States.
iCo Therapeutics logo

iCo Therapeutics

CVE:ICO
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.
AdvisorShares Q Portfolio Blended Allocation ETF logo

AdvisorShares Q Portfolio Blended Allocation ETF

NYSEARCA:QPT